Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023$19.5 million cash balance at Decem.